DOI:
10.1055/s-00035037
Methods of Information in Medicine
LinksClose Window
References
Jänne PA, Smith I, McWalter G, Mann H, Dougherty B, Walker J. et al.
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced nonsmall-cell lung cancer.
Br J Cancer 2015;
113 (02) 199-203.
We do not assume any responsibility for the contents of the web pages of other providers.